Evan Ballantyne

Evan Ballantyne currently serves as the Chief Financial Officer at Hansa Biopharma, a biopharmaceutical company specializing in treatments for rare immunological conditions, since March 2024. Prior to this role, Evan held positions including Senior Vice President and Chief Financial Officer at Gain Therapeutics, Chief Financial Officer and Business Development at OncXerna Therapeutics, and Chief Financial Officer at Orchestra BioMed. Evan's experience spans various companies in the biopharmaceutical and biotechnology sectors, including leadership roles at Agenus, Synthetic Biologics, and Clinical Data. Educational qualifications include a Bachelor of Arts in American History and Political Science from Western University, a Post Graduate Degree in Honors Business Administration from the University of Windsor, and continuing education in Finance and Financial Management Services from Wharton Executive Education.